Dublin, Ireland (PRWEB) February 28, 2013
Herceptin exclusivity is expiring in major geographies and many Biosimilar players (both experienced and new entrant) are looking to have a share of this potential $6billion pie. Herceptin sales are critical to Roche as it comprise about 15% of its cumulative Pharma sales. While eying for this potential lucrative opportunity, there are several risks and barriers that Biosimilar players should be aware. The report – “Risk – Reward of Developing a Herceptin biosimilar – A thorough assessment” looks into several aspects of potential opportunity size for Biosimilar players, with regard to:
For more information visit http://www.researchandmarkets.com/research/8p8bc7/risk_reward_of
Research and Markets
Laura Wood, Senior Manager.
Read the full story at http://www.prweb.com/releases/2013/2/prweb10478514.htm.
Copyright©2012 Vocus, Inc.
All rights reserved